HER2 Testing and Treatment Selection in Endometrial Cancer

Biomarker testing is presented as a central part of treatment planning in advanced and recurrent endometrial cancer. The faculty review why mismatch repair assessment remains foundational while broader molecular profiling, HER2 immunohistochemistry, and next generation sequencing are increasingly important when selecting later line therapy. Particular attention is given to HER2 expression and to the importance of recognizing potential candidates for trastuzumab deruxtecan before progression narrows treatment opportunities. The discussion underscores a major operational challenge in practice, which is that HER2 testing may still depend on an additional request rather than being built into standard workflows. That gap can delay appropriate treatment selection even as new data continue to expand the relevance of biomarker guided care. The broader point is that pathology processes and testing habits must evolve alongside the therapeutic landscape. A more proactive and comprehensive approach to biomarker assessment is becoming essential for individualized management of recurrent endometrial cancer.